Ceribell, Inc. logo

Ceribell, Inc. (CBLL)

Market Closed
17 Jul, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
18. 72
-0.42
-2.1944%
$
725.84M Market Cap
- P/E Ratio
- Div Yield
314,300 Volume
- Eps
$ 19.14
Previous Close
Add Transaction
Day Range
18.49 19.02
Year Range
10.85 24.33
Want to track CBLL and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

Summary

CBLL closed today lower at $18.72, a decrease of -2.1944% from yesterday's close, completing a monthly decrease of -3.7532% or -$0.73. Over the past 12 months, CBLL stock lost -14.4815%.
CBLL is not paying dividends to its shareholders.
The last earnings report, released on May 07, 2026, exceeded the consensus estimates by 0.3896%. On average, the company has surpassed earnings expectations by 0.1612%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on one exchange.

CBLL Chart

People also search for

Tyra Biosciences, Inc.
$ 32.13
+1.645%
Stoke Therapeutics Inc.
$ 29.05
-0.2061%
MBX
MBX Biosciences, Inc.
$ 62.92
+7.8875%
Sarepta Therapeutics Inc.
$ 17.22
-0.058%
BLU
BELLUS Health Inc
$ 14.74
+0.0339%
CeriBell Sees ‘Early Innings' Growth as Hospital Accounts and Usage Hit Records

CeriBell Sees ‘Early Innings' Growth as Hospital Accounts and Usage Hit Records

CeriBell NASDAQ: CBLL executives said the company's first-quarter results reflected continued momentum in both new account additions and increased usage among existing hospital customers, while outlining early progress in new clinical areas including neonatal seizure monitoring and delirium.

Marketbeat | 2 months ago
CeriBell, Inc. (CBLL) Q1 2026 Earnings Call Transcript

CeriBell, Inc. (CBLL) Q1 2026 Earnings Call Transcript

CeriBell, Inc. (CBLL) Q1 2026 Earnings Call Transcript

Seekingalpha | 2 months ago
CeriBell Q1 Earnings Call Highlights

CeriBell Q1 Earnings Call Highlights

CeriBell NASDAQ: CBLL reported first-quarter revenue growth of 29% and raised its full-year outlook, as management cited higher usage of its seizure monitoring system and the company's strongest quarter of net new hospital additions since becoming public.

Marketbeat | 2 months ago

Ceribell, Inc. Investors

Name Quantity Cost Value Profit ($) Gain (%)
CE
Curtis Ellergodt Rothschild Investment LLC
26 $570 $511.1 -$58.9 -10.33%
JD
Jim Dushek HARBOUR INVESTMENTS Inc.
1,500 $17,235 $29,435.4 $12,200.4 70.79%
Point72 Asset Management LP
Point72 Asset Management LP Point72 Asset Management LP
77,733 $1.42M $1.52M $95,611.48 6.71%
Joseph Castro
Joseph Castro Nuveen LLC
54,874 $1.03M $1.07M $42,574.98 4.14%
Bobby Adusumilli
Bobby Adusumilli SJS Investment Consulting Inc.
3 $54.99 $58.79 $3.8 6.91%

Ceribell, Inc. (CBLL) FAQ

What is the stock price today?

The current price is $18.72.

On which exchange is it traded?

Ceribell, Inc. is listed on NASDAQ (NGS).

What is its stock symbol?

The ticker symbol is CBLL.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 725.84M.

Has Ceribell, Inc. ever had a stock split?

No, there has never been a stock split.

Ceribell, Inc. Profile

Health Care Technology Industry
Healthcare Sector
Xingjuan Chao CEO
NASDAQ (NGS) Exchange
15678C102 CUSIP
US Country
327 Employees
- Last Dividend
- Last Split
- IPO Date

Overview

CeriBell, Inc. is a forward-thinking company that specializes in the creation of cutting-edge, AI-based point-of-care electroencephalography (EEG) technology, primarily designed for the detection and management of neurological conditions. Originally founded in 2014 under the name Brain Stethoscope, Inc., the company adopted its current name, CeriBell, Inc., in August 2015, marking a significant phase in its commitment to innovation in the medical technology arena. Positioned in Sunnyvale, California, CeriBell has focused its efforts on filling the void within the acute care setting, offering advanced solutions that cater to the previously unmet needs of patients suffering from neurological issues.

Products and Services

The CeriBell System: Developed as a novel, state-of-the-art, point-of-care EEG platform, the CeriBell System is designed to provide quick and efficient monitoring capabilities within acute care settings. This system stands out for its ability to deliver rapid diagnostics, which is crucial for the effective management and treatment of patients with neurological conditions. The incorporation of AI technologies within this platform underscores CeriBell’s commitment to pushing the boundaries of medical technology, aiming to offer smarter and more reliable diagnostic solutions.

EEG Disposable Headbands: As part of its product lineup, CeriBell offers disposable EEG headbands that are specifically engineered for ease of use and efficiency. These headbands are integral to the CeriBell System, ensuring that patients are monitored comfortably without the need for complex or time-consuming setup processes. Their disposable nature also highlights CeriBell’s attention to hygiene and patient safety, eliminating cross-contamination risks and encouraging the adoption of the system in various healthcare settings.

Pocket-Sized Battery-Operated Recorders: CeriBell's innovation streak extends to the development of compact, portable EEG recorders. These pocket-sized devices are battery-operated, emphasizing mobility and ease of use in various settings, including outpatient care or in environments where traditional EEG systems may be impractical. By making EEG technology more accessible and convenient, CeriBell aims to bridge the gap in neurological monitoring and care, enabling timely intervention and better patient outcomes.

Contact Information

Address: 360 North Pastoria Avenue
Phone: 800 436 0826